Lab21 to Develop microRNA-Based Colorectal Cancer Diagnostic for IntegraGen | GenomeWeb

British diagnostics service firmLab21 said this week that it has signed a deal to collaborate with diagnostics developer IntegraGen to develop a microRNA-based assay for colorectal cancer.

According to Lab21, it will use its proprietary PCR technology to develop an assay that can detect hsa-miR-31-3p, which is believed to predict response to EGFR inhibitor therapy, such as Erbitux, in KRAS wild-type patients with metastatic colorectal cancer.

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

A trial upgrade to GenomeWeb Premium gives you full site access, interest-based email alerts, access to archives, and more. Never miss another important industry story.

Try GenomeWeb Premium now.

Already a GenomeWeb Premium member? Login Now.
Or, See if your institution qualifies for premium access.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Register for Free Content
You can still register for access to our free content.

In Science this week: intellectual property landscape of CRISPR genome editing, and more.

A researcher has been convicted of conspiring to steal genetically engineered rice, Reuters reports.

Harvard Medical School's George Church says a woolly mammoth-elephant hybrid is only a few years away, according to the New Scientist.

Intel is ending its sponsorship of the International Science and Engineering Fair, the New York Times reports.